Skip to main content
. 2019 Sep 13;13:1545–1556. doi: 10.2147/PPA.S215037

Table 1.

Baseline characteristics of the study population

Characteristic PSP N=9851 Non-PSP N=7520 P-valuea
Age (years), mean ± SD 45.6±13.3 46.4±13.9 <0.001
Male, n (%) 3817 (38.7) 2935 (39.0) 0.71
Household income, n (%)
 $0–$49,999 1694 (17.2) 1486 (19.8) <0.001
 $50,000–$99,999 2778 (28.2) 2106 (28.0) 0.78
 >$100,000 2402 (24.4) 1480 (19.7) <0.001
 Unknown 2977 (30.2) 2448 (32.6) <0.001
Expected patient copay, mean ± SD $344±$1601 $627±$2042 <0.001
 $0–$25, n (%) 7685 (78.0) 4183 (55.6) <0.001
 $26–$100, n (%) 902 (9.2) 1581 (21.0) <0.001
 $101–$500, n (%) 437 (4.4) 586 (7.8) <0.001
 $501–$1000, n (%) 150 (1.5) 225 (3.0) <0.001
 $1001–$2000, n (%) 160 (1.6) 195 (2.6) <0.001
 >$2000, n (%) 517 (5.2) 750 (10.0) <0.001
Calendar year, n (%)
 2015 6152 (62.5) 5146 (68.4) <0.001
 2016 3699 (37.5) 2374 (31.6) <0.001
Primary plan, n (%)
 Commercial 3794 (38.5) 475 (6.3) <0.001
 Employer group 584 (5.9) 703 (9.3) <0.001
 Third party administrator 27 (0.3) 47 (0.6) <0.001
 Pharmacy benefit manager 1887 (19.2) 2432 (32.3) <0.001
 Cash 180 (1.8) 361 (4.8) <0.001
 Processors 41 (0.4) 71 (0.9) <0.001
 Unspecified or missing 3338 (33.9) 3431 (45.6) <0.001
Initial claim at specialty pharmacy, n (%)b 7443 (75.6) 3938 (52.4) <0.001
Charlson Comorbidity Index, mean ± SD 0.38±0.70 0.47±0.84 <0.001
Indications, n (%)
 Inflammatory bowel disease 4046 (41.1) 2446 (32.5) <0.001
 Rheumatoid arthritis 2475 (25.1) 2254 (30.0) <0.001
 Psoriasis 1844 (18.7) 1412 (18.8) 0.92
 Psoriatic arthritis 813 (8.3) 750 (10.0) <0.001
 Ankylosing spondylitis 246 (2.5) 304 (4.0) <0.001
 Hidradenitis suppurativa 314 (3.2) 217 (2.9) 0.25
 Uveitis 113 (1.1) 137 (1.8) <0.001

Notes: aWilcoxon rank-sum tests and chi-square tests were used to compare continuous and categorical variables, respectively. bDefined as a pharmacy type of mail order/specialty.

Abbreviations: PSP, patient support program; SD, standard deviation.